These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

652 related items for PubMed ID: 7636529

  • 1. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA, Herndon JE, Hollis DR, Ellerton J, Langleben A, Richards F, Green MR.
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [Abstract] [Full Text] [Related]

  • 2. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC.
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [Abstract] [Full Text] [Related]

  • 3. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonicolis J, Georgoulias V, Greek Lung Cancer Cooperative Group.
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 5. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK.
    Cancer; 1998 Jan 15; 82(2):301-8. PubMed ID: 9445186
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH.
    J Clin Oncol; 1995 Jul 15; 13(7):1615-22. PubMed ID: 7602350
    [Abstract] [Full Text] [Related]

  • 7. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
    Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A.
    J Clin Oncol; 2006 May 01; 24(13):2038-43. PubMed ID: 16648503
    [Abstract] [Full Text] [Related]

  • 8. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
    Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, Brannon S, Wissel P, Ross G.
    J Clin Oncol; 2006 May 01; 24(13):2044-51. PubMed ID: 16648504
    [Abstract] [Full Text] [Related]

  • 9. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P.
    Cancer; 2002 Oct 01; 95(7):1511-9. PubMed ID: 12237920
    [Abstract] [Full Text] [Related]

  • 10. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M, Mavroudis D, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, Agelidou A, Gerogianni A, Pavlakou G, Tselepatiotis E, Nikolakopoulos J, Georgoulias V.
    Clin Lung Cancer; 2005 Nov 01; 7(3):183-9. PubMed ID: 16354313
    [Abstract] [Full Text] [Related]

  • 11. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL.
    Clin Cancer Res; 1997 May 01; 3(5):719-25. PubMed ID: 9815741
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, Lee JS.
    J Clin Oncol; 2005 May 20; 23(15):3488-94. PubMed ID: 15908658
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.
    Zhou ZT, Zhou FX, Wei Q, Zou LY, Qin BF, Peng XS.
    Cancer Chemother Pharmacol; 2011 Oct 20; 68(4):1027-32. PubMed ID: 21327933
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
    Mavroudis D, Veslemes M, Kouroussis Ch, Tzanakis N, Ferdoutsis E, Toumbis M, Ziotopoulos P, Agelidou M, Tselepatiotis E, Kalbakis K, Souglakos J, Magkanas E, Samonis G, Georgoulias V, Hellenic Oncology Research Group.
    Lung Cancer; 2002 Oct 20; 38(1):59-63. PubMed ID: 12367794
    [Abstract] [Full Text] [Related]

  • 15. A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer.
    Johnson DH, Ruckdeschel JC, Keller JH, Lyman GH, Kallas GJ, Macdonald J, DeConti RC, Lee J, Ringenberg QS, Patterson WP.
    Cancer; 1991 Jan 01; 67(1 Suppl):245-9. PubMed ID: 1845847
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL, Marks RS, Mahoney MR, Sloan JA, Bauman MD, Tazelaar HD, Kugler JW, Mailliard JA, Ebbert LP, Wiesenfeld M.
    Am J Clin Oncol; 2003 Jun 01; 26(3):236-40. PubMed ID: 12796591
    [Abstract] [Full Text] [Related]

  • 17. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial.
    Maksymiuk AW, Jett JR, Earle JD, Su JQ, Diegert FA, Mailliard JA, Kardinal CG, Krook JE, Veeder MH, Wiesenfeld M.
    J Clin Oncol; 1994 Jan 01; 12(1):70-6. PubMed ID: 8270988
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS.
    Clin Lung Cancer; 2003 Jul 01; 5(1):40-5. PubMed ID: 14596703
    [Abstract] [Full Text] [Related]

  • 19. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec 01; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study.
    Loehrer PJ, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH.
    J Clin Oncol; 1995 Oct 01; 13(10):2594-9. PubMed ID: 7595712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.